Pfizer and BioNTech initiated tests of a new drug from the Omicron strain. The subjects are adults in the age group of 18-55 years.
During the tests, the criteria for safety, tolerability and immunogenicity of patients will be revealed. The drug was created to ensure safety from Omicron, which is actively spreading across the planet.
During the research, the test audience of 1420 people will be divided into several groups:
1. The first part of 615 participants are those who received 2 doses of vaccinations from Pfizer / BioNTech 3-6 months before the start of the tests. They will be given a maximum of two doses.
2. The next part (600 participants) is having 3 doses of Pfizer/BioNTech. They will receive a dose of an existing Pfizer/BioNTech drug or a newly developed vaccine
3. The rest is a group not vaccinated at all. They will be given 3 doses of the drug.
Earlier it became known about the development and testing of anti-corona drugs from other pharmaceutical companies. Information can be found here, here, here and here.
During the tests, the criteria for safety, tolerability and immunogenicity of patients will be revealed. The drug was created to ensure safety from Omicron, which is actively spreading across the planet.
During the research, the test audience of 1420 people will be divided into several groups:
1. The first part of 615 participants are those who received 2 doses of vaccinations from Pfizer / BioNTech 3-6 months before the start of the tests. They will be given a maximum of two doses.
2. The next part (600 participants) is having 3 doses of Pfizer/BioNTech. They will receive a dose of an existing Pfizer/BioNTech drug or a newly developed vaccine
3. The rest is a group not vaccinated at all. They will be given 3 doses of the drug.
Earlier it became known about the development and testing of anti-corona drugs from other pharmaceutical companies. Information can be found here, here, here and here.
Login or register to post comments
Comments 0